First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

被引：0
|
作者：
Mark, M. [1 ]
Froesch, P. [2 ]
Gysel, K. [3 ]
Rothschild, S. [4 ]
Addeo, A. [5 ]
Ackermann, C. [6 ]
Chiquet, S. [3 ]
Schneider, M. [3 ]
Ribi, K. [3 ]
Fischer, A. [1 ]
Bastian, S. [1 ]
von Moos, R. [7 ]
Joerger, M. [8 ]
Frueh, M. [8 ]
机构：
[1] Cantonal Hosp Graubunden, Oncol Hematol, Chur, Switzerland
[2] Cantonal Hosp Bellinzona, Oncol, Bellinzona, Switzerland
[3] SAKK, Coordinating Ctr, Bern, Switzerland
[4] Cantonal Hosp Baden, Oncol Hematol, Baden, Switzerland
[5] Geneva Univ Hosp, Oncol, Geneva, Switzerland
[6] Hosp Thun, Oncol Hematol, Thun, Switzerland
[7] Cantonal Hosp Graubunden, Tumor & Res Ctr, Chur, Switzerland
[8] Cantonal Hosp St Gallen, Oncol Hematol, St Gallen, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2023年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
218
引用
收藏
页码：7S / 7S
页数：1
相关论文
共 50 条
  • [41] Evaluation of PD-L1/PD-1 on circulating tumor cells (CTCs) and on primary tumor in advanced non-small cell lung cancer (NSCLC)
    Kallergi, Galaktea
    Vetsika, Eleni Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CANCER RESEARCH, 2017, 77
  • [42] Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%.
    Freemantle, Nicholas
    Xu, Yingxin
    Wilson, Florence
    Guyot, Patricia
    Chen, Chieh-I
    Keeping, Sam
    Konidaris, Gerasimos
    Chan, Keith
    Kuznik, Andreas
    Atsou, Kokuvi
    Glowienka, Emily
    Stow, Lisa
    Pouliot, Jean-Francois
    Gullo, Giuseppe
    Rietschel, Petra
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).
    Nandimandalam, Sujitha
    Sharma, Nitika
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
    Ozguroglu, Mustafa
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip R.
    Sriuranpong, Virote
    Rizvi, Naiyer A.
    McGinniss, Jennifer
    Pouliot, Jean-Francois
    Lee, Sue
    Seebach, Frank A.
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [46] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
    Rothschild, Sacha, I
    Zippelius, Alfred
    Eboulet, Eric, I
    Prince, Spasenija Savic
    Betticher, Daniel
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Lardinois, Didier
    Gelpke, Hans
    Mauti, Laetitia A.
    Britschgi, Christian
    Weder, Walter
    Peters, Solange
    Mark, Michael
    Cathomas, Richard
    Ochsenbein, Adrian F.
    Janthur, Wolf-Dieter
    Waibel, Christine
    Mach, Nicolas
    Froesch, Patrizia
    Buess, Martin
    Bohanes, Pierre
    Godar, Gilles
    Rusterholz, Corinne
    Gonzalez, Michel
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2872 - +
  • [47] Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
    Song, Zhengbo
    Lv, Dongqing
    Chen, Shi-Qing
    Huang, Jianjin
    Li, Yuping
    Ying, Shenpeng
    Wu, Xiaoyu
    Hua, Feng
    Wang, Wenxian
    Xu, Chunwei
    Bei, Ting
    Gao, Chan
    Sun, Zhijian
    Zhang, Yiping
    Lu, Shun
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 461 - 467
  • [48] BIWEEKLY DOCETAXEL AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND PERFORMANCE STATUS (PS) 2. A PHASE II STUDY OF THE GALICIAN LUNG CANCER GROUP
    Leon, L.
    Vazquez Estevez, S.
    Firvida, J. L.
    Casal, J.
    Garcia, J.
    Salgado, M.
    Huidobro, G.
    Vazquez, F.
    Perez, E.
    Baron, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 95 - 95
  • [49] Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
    Mienko, Fiona
    Halmos, Balazs
    Cheng, Haiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [50] SAKK 16/14-Perioperative Anti-PD-L1 Antibody Durvalumab in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC)
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2149 - S2149
12345